JP2021503486A - キナーゼ阻害剤化合物ならびに組成物および使用法 - Google Patents
キナーゼ阻害剤化合物ならびに組成物および使用法 Download PDFInfo
- Publication number
- JP2021503486A JP2021503486A JP2020527899A JP2020527899A JP2021503486A JP 2021503486 A JP2021503486 A JP 2021503486A JP 2020527899 A JP2020527899 A JP 2020527899A JP 2020527899 A JP2020527899 A JP 2020527899A JP 2021503486 A JP2021503486 A JP 2021503486A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- subject
- cell
- diabetes
- pancreatic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *NC(SC1)=NN=C1c(cc1)cc2c1NC1OC1N2 Chemical compound *NC(SC1)=NN=C1c(cc1)cc2c1NC1OC1N2 0.000 description 2
- FBMZADQAOVGFOE-UHFFFAOYSA-N CCCCNC(SC1)=NN=C1c(cc1)cc2c1NC1OC1N2 Chemical compound CCCCNC(SC1)=NN=C1c(cc1)cc2c1NC1OC1N2 FBMZADQAOVGFOE-UHFFFAOYSA-N 0.000 description 1
- NOCITULOFUAWNK-UHFFFAOYSA-N CN(c(ccc(C(OC)=O)c1)c1N1)C1=O Chemical compound CN(c(ccc(C(OC)=O)c1)c1N1)C1=O NOCITULOFUAWNK-UHFFFAOYSA-N 0.000 description 1
- PYEHNKXDXBNHQQ-UHFFFAOYSA-N CN(c1ccccc1N1)C1=O Chemical compound CN(c1ccccc1N1)C1=O PYEHNKXDXBNHQQ-UHFFFAOYSA-N 0.000 description 1
- KCWKTSHJBDLCSO-UHFFFAOYSA-N C[I](C)[O]1CCN(CCCN/C(/SCCc(cc2)cc(N3)c2NC3=O)=N/[N]#C)CC1 Chemical compound C[I](C)[O]1CCN(CCCN/C(/SCCc(cc2)cc(N3)c2NC3=O)=N/[N]#C)CC1 KCWKTSHJBDLCSO-UHFFFAOYSA-N 0.000 description 1
- IZZYGLIQBZQQSW-UHFFFAOYSA-N N#Cc1ccc(CNC(SC2)=NN=C2c(cc2)cc(N3)c2NC3=O)cc1 Chemical compound N#Cc1ccc(CNC(SC2)=NN=C2c(cc2)cc(N3)c2NC3=O)cc1 IZZYGLIQBZQQSW-UHFFFAOYSA-N 0.000 description 1
- XVJCMNPIXOVPIA-UHFFFAOYSA-N O=C(CCl)c(cc1)cc(N2)c1NC2=O Chemical compound O=C(CCl)c(cc1)cc(N2)c1NC2=O XVJCMNPIXOVPIA-UHFFFAOYSA-N 0.000 description 1
- KMRAAFBOCRRZJQ-UHFFFAOYSA-N O=C1Nc(cc(cc2)C3=NN=C(NCc4cc(cccc5)c5cc4)SC3)c2N1 Chemical compound O=C1Nc(cc(cc2)C3=NN=C(NCc4cc(cccc5)c5cc4)SC3)c2N1 KMRAAFBOCRRZJQ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762588792P | 2017-11-20 | 2017-11-20 | |
| US62/588,792 | 2017-11-20 | ||
| PCT/US2018/062023 WO2019100062A1 (en) | 2017-11-20 | 2018-11-20 | Kinase inhibitor compounds and compositions and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021503486A true JP2021503486A (ja) | 2021-02-12 |
| JP2021503486A5 JP2021503486A5 (cg-RX-API-DMAC10.html) | 2022-01-04 |
Family
ID=66539149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020527899A Pending JP2021503486A (ja) | 2017-11-20 | 2018-11-20 | キナーゼ阻害剤化合物ならびに組成物および使用法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11547712B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3717475B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2021503486A (cg-RX-API-DMAC10.html) |
| CN (1) | CN111936490A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2018368790A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3084581A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2019100062A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021510153A (ja) | 2018-01-05 | 2021-04-15 | アイカーン スクール オブ メディシン アット マウント サイナイ | 膵臓ベータ細胞の増殖を増加させる方法、治療方法、および組成物 |
| ES3038913T3 (en) | 2018-03-20 | 2025-10-15 | Icahn School Med Mount Sinai | Beta-carboline derivatives as dyrk1a inhibitors for the treatment of e.g. diabetes |
| WO2025231425A1 (en) * | 2024-05-03 | 2025-11-06 | Biosplice Therapeutics, Inc. | 4-aminopyrrolo[2,l-f][l,2,4]triazines and preparation and uses thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011006408A (ja) * | 2009-05-29 | 2011-01-13 | Sumitomo Chemical Co Ltd | 神経栄養因子の活性が関与する疾患の治療または予防剤 |
| US20150174034A1 (en) * | 2013-03-13 | 2015-06-25 | Avon Products, Inc. | Tyrosinase inhibitors |
| JP2016521762A (ja) * | 2013-06-18 | 2016-07-25 | 4エスツェー ディスカバリー ゲゼルシャフト ミット ベシュレンクテル ハフツング | Dyrkキナーゼ阻害剤としての2,3−ジヒドロベンゾフラン−5−イル化合物 |
| WO2017040993A1 (en) * | 2015-09-03 | 2017-03-09 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of dyrk1a and uses thereof |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200301123A (en) | 2001-12-21 | 2003-07-01 | Astrazeneca Uk Ltd | New use |
| WO2004026306A2 (en) | 2002-09-18 | 2004-04-01 | Pfizer Products Inc. | Pyrazole derivatives as transforming growth factor (tgf) inhibitors |
| JP4896518B2 (ja) | 2002-12-13 | 2012-03-14 | ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド | ニコチンアミド系キナーゼ阻害薬 |
| AU2003297460A1 (en) | 2002-12-19 | 2004-07-14 | Scios, Inc. | TREATMENT OF OBESITY AND ASSOCIATED CONDITIONS WITH TGF-Beta INHIBITORS |
| US20050032869A1 (en) | 2003-07-08 | 2005-02-10 | Pharmacia Italia S.P.A. | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| US20090196912A1 (en) | 2004-07-30 | 2009-08-06 | Gpc Botech Ag | Pyridinylamines |
| DK1789044T3 (da) | 2004-09-06 | 2010-12-06 | Basilea Pharmaceutica Ag | Phenylaminopyridiner og phenylaminopyraziner |
| WO2007084667A2 (en) | 2006-01-19 | 2007-07-26 | Osi Pharmaceutical, Inc. | Fused heterobicyclic kinase inhibitors |
| BRPI0807961A2 (pt) | 2007-02-13 | 2017-05-16 | Pharmacopeia Llc | agonista de alfa2c adrenorreceptor funcionalmente seletivos. |
| GB0705566D0 (en) | 2007-03-23 | 2007-05-02 | Univ Dundee | Method of treating learning impairment in down's syndrome subjects |
| EP2178537A4 (en) | 2007-07-19 | 2011-08-17 | Merck Sharp & Dohme | BETA-CARBOLIN DERIVATIVES AS ANTIDIBLE COMPOUNDS |
| EP2265603B1 (en) | 2008-03-13 | 2014-05-07 | The General Hospital Corporation | Inhibitors of the bmp signaling pathway |
| US20100173931A1 (en) | 2009-01-06 | 2010-07-08 | Osteogenex Inc. | Harmine derivatives for reducing body weight |
| WO2010123583A2 (en) | 2009-04-24 | 2010-10-28 | University Of Tennessee Research Foundation | 1-aryl or 1-heteroaryl-pyrido[b]indoles and uses thereof |
| AU2010247412A1 (en) | 2009-05-15 | 2011-11-24 | Novartis Ag | 5-pyridin-3-yl-1,3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or CYP11B1 |
| WO2010135589A2 (en) | 2009-05-20 | 2010-11-25 | Sakura Properties, Llc | Dietary supplement drink for delivery of resveratrol and other polyphenols |
| CN102791134B (zh) | 2009-12-04 | 2015-04-22 | 魄金莱默有限公司 | 用多巴胺再摄取抑制剂及类似物治疗糖尿病症状和延迟或预防糖尿病相关病理学病况的方法 |
| WO2011075665A2 (en) | 2009-12-18 | 2011-06-23 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
| US20130102627A1 (en) | 2010-04-09 | 2013-04-25 | The Brigham And Women's Hospital, Inc. | Acridines As Inhibitors Of Haspin And DYRK Kinases |
| WO2011133795A2 (en) | 2010-04-22 | 2011-10-27 | The Brigham And Women's Hospital, Inc. | Beta-carbolines as inhibitors of haspin and dyrk kinases |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
| MX341025B (es) | 2010-05-05 | 2016-08-04 | Boehringer Ingelheim Int Gmbh * | Terapia de combinacion. |
| US9168247B2 (en) | 2010-06-25 | 2015-10-27 | Facultes Universitaires Notre Dame De La Paix | Beta carboline derivatives useful in the treatment of proliferative disorders |
| AU2011290123B2 (en) | 2010-08-09 | 2016-11-10 | Takeda Pharmaceutical Company Limited | Method of producing pancreatic hormone-producing cells |
| US20130165474A1 (en) | 2010-08-17 | 2013-06-27 | Travis Dunckley | Compounds that inhibit tau phosphorylation |
| KR102006749B1 (ko) | 2011-08-19 | 2019-08-02 | 디악쏘니 | Dyrk1 억제제 및 이의 용도 |
| CN103070862A (zh) | 2011-10-25 | 2013-05-01 | 新疆华世丹药物研究有限责任公司 | 去氢骆驼蓬碱衍生物在制备抗菌药物中的应用 |
| WO2013119518A1 (en) | 2012-02-06 | 2013-08-15 | The Regents Of The University Of California | Small molecules for islet expansion |
| AU2013284460A1 (en) | 2012-06-27 | 2015-01-29 | Dmnomore | CTLA4 fusion proteins for the treatment of diabetes |
| CN105142621A (zh) | 2012-10-24 | 2015-12-09 | 国家健康科学研究所 | 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂 |
| JP2016500080A (ja) | 2012-11-26 | 2016-01-07 | 新疆華世丹薬物研究有限責任公司 | ビスβ−カルボリン系化合物、その製造方法、医薬組成物および用途 |
| JPWO2014058080A1 (ja) | 2012-11-30 | 2016-09-05 | 国立研究開発法人理化学研究所 | 体細胞のリプログラミングを亢進させる方法、及び細胞作製キット |
| CN102977096B (zh) | 2012-12-07 | 2014-12-17 | 中国药科大学 | 具有靶向特性的去氢骆驼蓬碱衍生物的抗肿瘤前药 |
| MX2015007097A (es) | 2012-12-10 | 2015-09-29 | Hoffmann La Roche | Nuevas fenil-piridinas/pirazinas bi-anulares para el tratamiento de cancer. |
| SI2968284T1 (sl) | 2013-03-14 | 2021-08-31 | Osteoqc Inc. | Alkil-amin harmin derivati za pospeševanje rasti kosti |
| WO2014151682A1 (en) | 2013-03-14 | 2014-09-25 | Icahn School Of Medicine At Mount Sinai | Pyrimidine compounds as kinase inhibitors |
| GB2519623A (en) | 2013-06-18 | 2015-04-29 | 4Sc Discovery Gmbh | Method of inhibiting DYRK1B |
| US9725463B2 (en) | 2013-06-21 | 2017-08-08 | Lupin Limited | Substituted heterocyclic compounds as CRAC modulators |
| ES2529865B8 (es) | 2013-07-25 | 2016-01-22 | Fundación Para La Investigación Biomédica Del Hospital Universitario La Paz (Fibhulp) | USO DE COMPUESTOS DERIVADOS DE SALES DE PIRIDAZINO[1',6':1,2]PIRIDO[3,4-b]INDOLINIO COMO AGENTES ANTIINFLAMATORIOS |
| SI3057959T1 (en) | 2013-10-17 | 2018-07-31 | Vertex Pharmaceuticals Incorporated | DNA-PK INHIBITORS |
| JP6767875B2 (ja) | 2014-04-08 | 2020-10-14 | ライジェル ファーマシューティカルズ, インコーポレイテッド | Tgf−ベータ阻害剤としての2,3−二置換ピリジン化合物および使用方法 |
| US20170280720A1 (en) | 2014-09-17 | 2017-10-05 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| ES2985135T3 (es) | 2014-12-18 | 2024-11-04 | Harvard College | Procedimientos para generar células ß derivadas de células madre y usos de las mismas |
| ES2820768T3 (es) | 2015-04-03 | 2021-04-22 | Xoma Technology Ltd | Tratamiento del cáncer usando inhibidores de TGF-beta y PD-1 |
| US11332716B2 (en) | 2015-07-27 | 2022-05-17 | The Regents Of The University Of California | Methods and compositions for producing pancreatic beta cells |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| CN105884767B (zh) | 2015-11-24 | 2018-01-19 | 西华大学 | 9‑位取代的吡啶并[3,4‑b]吲哚衍生物及其制备方法和作为SIRT蛋白抑制剂的用途 |
| EP3389720A1 (en) | 2015-12-18 | 2018-10-24 | The General Hospital Corporation | Polyacetal polymers, conjugates, particles and uses thereof |
| US10487087B2 (en) | 2015-12-30 | 2019-11-26 | Vanderbilt University | Positive allosteric modulators of the GLP-1 receptor |
| WO2017168245A1 (en) | 2016-04-01 | 2017-10-05 | University Of Limerick | Pharmaceutical compositions and methods for the treatment of diabetes |
| WO2017197151A1 (en) | 2016-05-11 | 2017-11-16 | Emory University | Phosphotidylinositol 3-kinase inhibitors |
| WO2018081401A1 (en) | 2016-10-26 | 2018-05-03 | Ichan School Of Medicine At Mount Sinai | Method for increasing cell proliferation in pancreatic beta cells, treatmen t method.and composition |
| EP3318563A1 (en) | 2016-11-07 | 2018-05-09 | Sanofi | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders |
| US11279703B2 (en) | 2016-12-01 | 2022-03-22 | Aptose Biosciences Inc. | Fused pyrimidine compounds as BRD4 and JAK2 dual inhibitors and methods for use thereof |
| JP2021510153A (ja) | 2018-01-05 | 2021-04-15 | アイカーン スクール オブ メディシン アット マウント サイナイ | 膵臓ベータ細胞の増殖を増加させる方法、治療方法、および組成物 |
| ES3038913T3 (en) | 2018-03-20 | 2025-10-15 | Icahn School Med Mount Sinai | Beta-carboline derivatives as dyrk1a inhibitors for the treatment of e.g. diabetes |
| CA3124700A1 (en) | 2018-12-31 | 2020-07-09 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| CA3124353A1 (en) | 2018-12-31 | 2020-07-09 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
-
2018
- 2018-11-20 WO PCT/US2018/062023 patent/WO2019100062A1/en not_active Ceased
- 2018-11-20 US US16/765,542 patent/US11547712B2/en active Active
- 2018-11-20 CA CA3084581A patent/CA3084581A1/en active Pending
- 2018-11-20 CN CN201880087073.5A patent/CN111936490A/zh active Pending
- 2018-11-20 EP EP18878625.5A patent/EP3717475B1/en active Active
- 2018-11-20 JP JP2020527899A patent/JP2021503486A/ja active Pending
- 2018-11-20 AU AU2018368790A patent/AU2018368790A1/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011006408A (ja) * | 2009-05-29 | 2011-01-13 | Sumitomo Chemical Co Ltd | 神経栄養因子の活性が関与する疾患の治療または予防剤 |
| US20150174034A1 (en) * | 2013-03-13 | 2015-06-25 | Avon Products, Inc. | Tyrosinase inhibitors |
| JP2016521762A (ja) * | 2013-06-18 | 2016-07-25 | 4エスツェー ディスカバリー ゲゼルシャフト ミット ベシュレンクテル ハフツング | Dyrkキナーゼ阻害剤としての2,3−ジヒドロベンゾフラン−5−イル化合物 |
| WO2017040993A1 (en) * | 2015-09-03 | 2017-03-09 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of dyrk1a and uses thereof |
Non-Patent Citations (2)
| Title |
|---|
| KUNAL KUMAR; ET AL: "NOVEL SELECTIVE THIADIAZINE DYRK1A INHIBITOR LEAD SCAFFOLD WITH HUMAN PANCREATIC 以下備考", EUR J MED CHEM, vol. 157, JPN5021003596, 22 August 2018 (2018-08-22), pages 1005 - 1016, XP085491737, ISSN: 0004900864, DOI: 10.1016/j.ejmech.2018.08.007 * |
| SYNTHETIC COMMUNICATIONS, vol. 42, JPN6022044409, 2012, pages 1454 - 1460, ISSN: 0004900865 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3717475B1 (en) | 2023-06-07 |
| AU2018368790A1 (en) | 2020-06-25 |
| WO2019100062A1 (en) | 2019-05-23 |
| US20200306257A1 (en) | 2020-10-01 |
| EP3717475A1 (en) | 2020-10-07 |
| CN111936490A (zh) | 2020-11-13 |
| US11547712B2 (en) | 2023-01-10 |
| CA3084581A1 (en) | 2019-05-23 |
| EP3717475A4 (en) | 2021-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12421232B2 (en) | Kinase inhibitor compounds and compositions and methods of use | |
| KR101892574B1 (ko) | 디아릴아세틸렌 히드라지드 함유 티로신 키나제 억제제 | |
| TW202039489A (zh) | Mat2a之雜雙環抑制劑及用於治療癌症之使用方法 | |
| AU2011217561B2 (en) | Hetarylaminonaphthyridines | |
| KR102011770B1 (ko) | 치환된 피리도피리미딘 화합물 및 flt3 억제제로서의 이의 용도 | |
| US20230234935A1 (en) | Kinase inhibitor compounds and compositions and methods of use | |
| JP2022515650A (ja) | キナーゼ阻害剤化合物及び組成物ならびに使用方法 | |
| EP3906233B1 (en) | Kinase inhibitor compounds and compositions and methods of use | |
| US20140371251A1 (en) | Method of inhibiting dyrk1b | |
| EP3717475B1 (en) | Kinase inhibitor compounds and compositions and methods of use | |
| WO2002076396A2 (en) | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases | |
| HK40063467A (en) | Kinase inhibitor compounds and compositions and methods of use | |
| HK40062251A (en) | Kinase inhibitor compounds and compositions and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20210324 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211119 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20211119 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20221013 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221020 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230118 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230615 |